Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes - Summary - MDSpire
Advertisement
Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes
To compare the effects of SGLT2 inhibitors and GLP-1 receptor agonists on liver enzyme levels (specifically ALT and AST) in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Key Findings:
SGLT2is treatment resulted in greater reductions in ALT (-10.55 U/L) compared to GLP-1RAs (-7.28 U/L, p=0.011).
SGLT2is also showed greater reductions in AST (-7.68 U/L) compared to GLP-1RAs (-5.18 U/L, p=0.010).
No significant differences were found in changes in GGT, body weight, glycemic control, or lipid profiles between the two groups.
Interpretation:
SGLT2 inhibitors are associated with greater reductions in liver enzymes compared to GLP-1 receptor agonists in patients with T2D and NAFLD, suggesting potential direct hepatoprotective effects that may influence treatment decisions.
Limitations:
The study is retrospective and may be subject to selection bias, potentially affecting the generalizability of the results.
The cohort was limited to patients who initiated monotherapy, which may not represent the broader population.
Conclusion:
SGLT2 inhibitors are associated with greater reductions in ALT and AST than GLP-1 receptor agonists in T2D patients with NAFLD, indicating potential direct benefits for liver health.
